Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal
A bidding war has suddenly erupted over one of the most damaged biotechs in gene therapy R&D.
Just weeks after Regenxbio lined up the acquisition of Dimension Therapeutics $DMTX for $86 million in stock, Ultragenyx $RARE has come along with an offer of $5.50 a share, significantly more than what Regenxbio $RGNX had offered ($3.41) and a 358% premium over what Dimension’s shares were trading for ahead of the earlier buyout announcement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.